‹
›
This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
The Beacon
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
30
00:00:00
/ 00:04:13
30